468 related articles for article (PubMed ID: 36139583)
1. MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.
Bartolucci D; Montemurro L; Raieli S; Lampis S; Pession A; Hrelia P; Tonelli R
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139583
[TBL] [Abstract][Full Text] [Related]
2. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
3. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
4. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
5. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
6. RNA N
Cheng J; Xu L; Deng L; Xue L; Meng Q; Wei F; Wang J
Sci Rep; 2020 Aug; 10(1):13624. PubMed ID: 32788584
[TBL] [Abstract][Full Text] [Related]
7. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
8. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
9. The impact of surgical radicality on outcome in childhood neuroblastoma.
von Schweinitz D; Hero B; Berthold F
Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
[TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
11. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
12. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
13. Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.
Keane S; Améen S; Lindlöf A; Ejeskär K
Cell Commun Signal; 2020 Apr; 18(1):65. PubMed ID: 32312269
[TBL] [Abstract][Full Text] [Related]
14. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
[TBL] [Abstract][Full Text] [Related]
15. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
[TBL] [Abstract][Full Text] [Related]
16.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
17. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
18. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma].
Fan X; Lu HT; Hou L; Zhang L; Yang BY; Chen WM; Zhang HY; Chen X; Li FJ
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Mar; 22(3):262-268. PubMed ID: 32204764
[TBL] [Abstract][Full Text] [Related]
19. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
20. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]